ArticleFrontiers in microbiology2025
Integrative network pharmacology, metabolomics and gut flora studies reveal mechanisms of action of
Article in Frontiers in microbiology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- A review ofFrontiers in pharmacology · 2026Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Liver injury (LI) is responsible for a significant number of fatalities each year. In the context of Mongolian medicine, Objectives: Clarifying the process through which RM enhances LI. Methods: The chemical constituents were subjected to analysis, and network pharmacology alongside molecular docking studies were conducted. Additionally, ELISA, staining techniques, metabolomic analyses, and 16S rDNA sequencing were performed. Results: A total of 17 components have been identified from RM, including liver disease-related compounds such as kaempferol, emodin, quercetin. Network pharmacology has identified notable genes that exhibit a strong binding affinity to active compounds, including emodin, which interacts with IL6 and PPARG, and aloeemodin, which binds to IL6 and AKT1. In a rat model of LI induced by CCL Conclusion: RML has the potential to enhance the composition of intestinal microbiota by through the differential regulation of various metabolized components, including 13-OxoODE, morphine, and niacinamide, it influences several metabolic pathways, notably steroid biosynthesis, lysine degradation, interconversions of pentose and glucuronate, as well as the metabolism of linoleic acid. Additionally, it may promote the proliferation of
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.